评估常规产后人乳头瘤病毒 (HPV) 疫苗接种是否可接受和可行，并确定可用于提高产后 HPV 疫苗接种率的关键主题和策略。从成立到 2024 年 7 月对 PubMed 和 ClinicalTrials.gov 进行了产后和 HPV 疫苗接种的查询。研究仅限于人类受试者和英语。对任何评估产后 HPV 疫苗接种的方法的研究进行了筛选 (N=60)。仅包括报告 HPV 疫苗的吸收或可接受性的原始研究。 39 项研究在摘要审查后被淘汰，因为它们不符合纳入标准。 9 项研究根据研究的主要目的（定义问题、评估患者观点或测试增加疫苗接种的干预措施）进行分类，并证明产后HPV疫苗接种计划可以显着提高HPV疫苗接种率，并且对患者来说是可行和可接受的。将HPV疫苗接种纳入标准产后护理，为接触弱势患者群体提供了机会，降低了患者的成本，并具有预防HPV相关癌症的能力。版权© 2024 美国妇产科学院版权所有。由 Wolters Kluwer Health, Inc. 出版。保留所有权利。

To assess whether routine postpartum human papillomavirus (HPV) vaccination is acceptable and feasible and to identify key themes and strategies that can be used to increase postpartum HPV vaccination rates.PubMed and ClinicalTrials.gov were queried from inception to July 2024 for postpartum and HPV vaccination. Studies were limited to human subjects and the English language.Screening was performed for studies of any method that evaluated HPV vaccination in the postpartum period (N=60). Only original research that reported either uptake or acceptability of the HPV vaccine was included. Thirty-nine studies were eliminated after abstract review because they did not meet the inclusion criteria.Nine studies were categorized according to the primary aim of the study (defining the problem, assessing patient perspectives, or testing interventions to increase vaccination) and demonstrated that postpartum HPV vaccination programs can significantly increase HPV vaccination rates and are feasible and acceptable to patients.Incorporating HPV vaccination into standard postpartum care provides an opportunity to reach vulnerable patient populations, reduces cost for patients, and has the ability to prevent HPV-related cancers.Copyright © 2024 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.